Cell
Rentschler Biopharma Exits Cell and Gene Therapy Sector, Refocuses on Biologics Manufacturing
Rentschler Biopharma, strategic realignment, cell and gene therapy, biologics manufacturing, CDMO, market demand, Stevenage facility closure
Vigil Neuroscience’s Oral Alzheimer’s Candidate VG-3927 Shows Promising Phase 1 Results with Sanofi’s Strategic Support
Vigil Neuroscience, VG-3927, Alzheimer’s disease, Phase 1 clinical trial, Sanofi strategic investment, TREM2 agonist program, Microglia therapy
AbbVie and Simcere Zaiming Collaborate on Novel Trispecific Antibody for Multiple Myeloma Treatment
AbbVie, Simcere Zaiming, multiple myeloma, trispecific antibody, SIM0500, T-cell engager, GPRC5D, BCMA, CD3
Ouro Medicines Launches with $120M Funding to Develop Immune Reset Therapeutics for Chronic Immune-Mediated Diseases
Ouro Medicines, Immune Reset Therapeutics, Chronic Immune-Mediated Diseases, T Cell Engagers, B Cell Mediated Diseases, GSK, Monograph Capital, TPG Life Sciences Innovations, NEA, Norwest Venture Partners
Synaffix Expands ADC Licensing Partnerships with Boehringer Ingelheim and Mitsubishi Tanabe
Synaffix, Boehringer Ingelheim, Mitsubishi Tanabe, ADC technology, oncology, cancer treatment, licensing agreement
Roche’s Chugai Enters $780M Deal with Swiss ADC Specialist Araris Biotech
Roche, Chugai, Araris Biotech, ADC, Antibody-Drug Conjugate, Biotech Deal
WuXi AppTec Divests Cell and Gene Therapy Units to Altaris in Strategic Shift
WuXi AppTec, Cell and Gene Therapy, Altaris, Strategic Divestment, Biosecure Act, Pharmaceutical Outsourcing
Biopharmaceutical Manufacturing and Emerging Trends in 2024: A Global Outlook
Biopharmaceutical manufacturing, 2024 trends, personalized medicine, AI-driven drug discovery, biosimilars, cell and gene therapies, biotechnology innovations.
Candid Therapeutics Expands T-Cell Engager Pipeline with Strategic Collaborations
T-cell engagers, autoimmune diseases, biotechnology, Candid Therapeutics, collaborations, EpimAb Biotherapeutics, Nona Biosciences
Candid Therapeutics Expands T-Cell Engager Portfolio with Three New R&D Collaborations
Candid Therapeutics, T-cell engagers (TCEs), autoimmune diseases, R&D collaborations, biotechnology partnerships